On the other hand, the combination of inotuzumab ozogamicin (InO), an ADC that covalently conjugates calicheamicin to a humanized anti-CD22 antibody, and salvage chemotherapy (mini-hyper-fractionated cyclophosphamide, vincristine, and dexamethasone [mini-hyper-CVD]) with or without blinatumomab was superior to InO or the chemotherapy alone in relapsed or refractory ALL [62]. Here, CD22 is linked to acute lymphoblastic leukemia.